Opinion: Joseph Fraumeni Jr., pioneering cancer genetics researcher, devoted his life to families like mine

Joseph Fraumeni Jr. dedicated his career to cancer genetics research, a path he chose after an early experience in medical school steered him away from surgery. Fraumeni, who passed away on August 10, 2024, became a pivotal figure at the National Cancer Institute (NCI), where he served for over six decades. His foundational work involved establishing the NCI's first clinical genetics section in 1967, which later evolved into the Human Genetics Branch. Throughout his tenure, Fraumeni led extensive epidemiological studies, notably the 1959-1960 study of childhood cancer clusters in Massachusetts, which helped identify environmental and genetic factors contributing to cancer development. He was instrumental in recognizing hereditary cancer syndromes, including Li-Fraumeni syndrome, which he co-described in 1969 with Frederick Li. This syndrome, characterized by a high lifetime risk of developing multiple cancers, highlighted the critical role of inherited genetic mutations, specifically in the TP53 gene, in cancer predisposition. His research provided crucial insights into the molecular basis of cancer and informed genetic counseling and early detection strategies for families at increased risk. Fraumeni's commitment extended to mentoring numerous researchers and clinicians, fostering a collaborative environment that advanced the understanding of cancer's genetic underpinnings.